vs
Side-by-side financial comparison of Viridian Therapeutics, Inc.\DE (VRDN) and ZK International Group Co., Ltd. (ZKIN). Click either name above to swap in a different company.
ZK International Group Co., Ltd. is the larger business by last-quarter revenue ($108.2M vs $70.6M, roughly 1.5× Viridian Therapeutics, Inc.\DE). ZK International Group Co., Ltd. runs the higher net margin — -2.6% vs -49.0%, a 46.5% gap on every dollar of revenue. ZK International Group Co., Ltd. produced more free cash flow last quarter ($-7.5M vs $-84.7M).
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
ZK International Group Co., Ltd. is a China-based enterprise focused on the research, development, design, manufacturing and sale of high-quality stainless steel piping systems and fluid transport supporting products. Its offerings cater to construction, municipal infrastructure and residential engineering segments, with core markets spanning China and selected overseas regions.
VRDN vs ZKIN — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $70.6M | $108.2M |
| Net Profit | $-34.6M | $-2.8M |
| Gross Margin | — | 6.1% |
| Operating Margin | -56.7% | -1.6% |
| Net Margin | -49.0% | -2.6% |
| Revenue YoY | 81958.1% | — |
| Net Profit YoY | 54.9% | — |
| EPS (diluted) | — | $-0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $490.9M | $4.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $503.0M | $28.2M |
| Total Assets | $577.1M | $80.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $490.9M | — | ||
| Q3 24 | — | $4.1M |
| Q3 25 | $503.0M | — | ||
| Q3 24 | — | $28.2M |
| Q3 25 | $577.1M | — | ||
| Q3 24 | — | $80.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-84.6M | $-6.9M |
| Free Cash FlowOCF − Capex | $-84.7M | $-7.5M |
| FCF MarginFCF / Revenue | -120.1% | -6.9% |
| Capex IntensityCapex / Revenue | 0.2% | 0.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-84.6M | — | ||
| Q3 24 | — | $-6.9M |
| Q3 25 | $-84.7M | — | ||
| Q3 24 | — | $-7.5M |
| Q3 25 | -120.1% | — | ||
| Q3 24 | — | -6.9% |
| Q3 25 | 0.2% | — | ||
| Q3 24 | — | 0.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
